The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors

被引：0
|
作者：
El-Khoueiry, Anthony B.
Song, Paul Y.
Rubel, Jennifer
Pourang, Dorna Y.
Raab, Christa
Hintzen, Gabriele
Emig, Michael
Nava-Parada, Pilar
机构：
[1] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[2] NKGen BioTech Inc, Santa Ana, CA USA
[3] Affimed Inc, New York, NY USA
[4] Affimed GmbH, Heidelberg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2675
引用
收藏
页数：1
相关论文
共 36 条
  • [21] USFDA authorized compassionate use of SNK01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) and checkpoint inhibitors in advanced heavily pre-treated sarcoma: A promising regimen
    Chua, V. S.
    Chawla, S. P.
    Gordon, E.
    Kim, T. T.
    Gibson, B.
    Chang, P.
    Song, P. Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S890 - S890
  • [22] Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies
    Reusch, Uwe
    Ellwanger, Kristina
    Fucek, Ivica
    Mueller, Thomas
    Schniegler-Mattox, Ute
    Pahl, Jens
    Tesar, Michael
    Koch, Joachim
    BLOOD, 2021, 138
  • [23] The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study
    Choi, Myeong Geun
    Son, Gun Woo
    Ko, Dae-Hyun
    Ji, Wonjun
    Rho, Jin Kyung
    Lee, Jae Cheol
    Kim, Yong Man
    Jung, Jae Seob
    Song, Paul Y.
    Yoon, Byeong Gon
    Jo, Jong-Min
    Choi, Mi Young
    Choi, Chang-Min
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study
    Choi, Myeong Geun
    Son, Gun Woo
    Choi, Mi Young
    Jung, Jae Seob
    Rho, Jin Kyung
    Ji, Wonjun
    Yoon, Byeong Gon
    Jo, Jong-Min
    Kim, Yong Man
    Ko, Dae-Hyun
    Lee, Jae Cheol
    Choi, Chang-Min
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [25] A randomized phase I/IIa study to evaluate the safety and efficacy of SNK01 (non-genetically modified autologous natural killer cells with enhanced cytotoxicity) plus pembrolizumab in patients with stage IV non-small cell lung cancer.
    Kim, Eo Jin
    Ko, Dae-Hyun
    Ji, Wonjun
    Rho, Jin Kyung
    Lee, Jae Cheol
    Song, Paul Y.
    Choi, Chang-Min
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P plus E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results
    Nieto, Yago
    Banerjee, Pinaki
    Kaur, Indreshpal
    Griffin, Lori
    Barnett, Melissa
    Ganesh, Christina
    Borneo, Zephanie
    Bassett, Roland L.
    Kerbauy, Lucila Nassif
    Basar, Rafet
    Kaplan, Mecit
    Esqueda, Daniel
    Ramdial, Jeremy
    Ahmed, Sairah
    Hosing, Chitra
    Srour, Samer A.
    Alousi, Amin
    Qazilbash, Muzaffar H.
    Steiner, Raphael Eric
    Alexis, Karenza
    Emig, Michael
    Harstrick, Andreas
    Shpall, Elizabeth J.
    Rezvani, Katayoun
    BLOOD, 2023, 142
  • [27] CLINICAL EFFICACY OF KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR LIGAND-MISMATCHED ALLOGENEIC NATURAL KILLER CELLS IN PATIENTS WITH MALIGNANT LYMPHOMA OR ADVANCED SOLID TUMORS
    Lim, O.
    Choi, H.
    Chung, H.
    Mine, B.
    Her, J.
    Cho, S.
    Hwang, Y.
    CYTOTHERAPY, 2017, 19 (05) : S38 - S39
  • [28] Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion
    Chua, Victoria
    Chawla, Sant P.
    Gordon, Erlinda Maria
    Feske, William
    Hui, Lucia
    Lee, Hank
    Kang, Yoonmi
    Mata, Juan
    Betito, Katia
    Chang, Paul Y.
    Song, Paul Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] PRELIMINARY SAFETY AND EFFICACY OF AUTOLOGOUS ANTI-MSLN T CELL ENGAGER-LOADED T CELLS (CAB-T) IN PATIENTS WITH MESOTHELIN-EXPRESSING ADVANCED SOLID TUMORS
    Bao, Xuanwen
    Liu, Lulu
    Gu, Jialin
    Li, Mei
    Tong, Zhou
    Zhang, Hangyu
    Li, Yalin
    Gong, Xinjiang
    Wang, Peng
    Tsun, Andy
    Hu, Guoqiang
    Chou, Chuan-Chu
    Li, Zhiyuan
    Fang, Weijia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A210 - A210
  • [30] Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors
    Carneiro, Benedito
    Garmezy, Benjamin
    Hamm, John T.
    Sanborn, Rachel E.
    Wise-Draper, Trisha
    El-Khoueiry, Anthony
    Wilky, Breelyn
    Hoon, Dave S. B.
    Buffa, Alexa
    Michelet, Xavier
    Purbhoo, Marco
    Exley, Mark A.
    Einstein, David
    CANCER RESEARCH, 2023, 83 (08)
1234